EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

A First-in-Human Phase 1 Clinical Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of EDI048, a Novel Promising Agent to Treat Enteric Cryptosporidiosis

Monish Jain, Kristen Stevenson, Anais Cheblal, Ganesh Iyer, Rahmanzadeh Gholamreza, Jean-Rene Galarneau, Sofia Braud-Perez, Rajiv S Jumani iD, Johanne Blais iD, Joseph Etse iD, Juergen Dederichs, Yiming Zhang und 5 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag210 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Monish Jain und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research, Novartis, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Cryptosporidiosis, Antiprotozoal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis BioMedical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cryptosporidiosis is a major diarrheal disease with significant morbidity and mortality in children from low- and middle-income countries. EDI048, a novel Cryptosporidium PI(4)K inhibitor, is designed to act in the gastrointestinal tract and undergo rapid hepatic metabolism to minimize systemic exposure. This study evaluated the safety, tolerability, pharmacokinetics (PK), and effect of food on PK of EDI048 and its metabolites in healthy adult volunteers.

Methods

In a randomized, placebo-controlled, single and multiple ascending dose trial, healthy adults received EDI048 at 45-, 180-, and 400 mg doses while fasting and a single 400-mg dose in fasted and fed states to evaluate safety and tolerability. Plasma PK was analyzed for EDI048 and 2 inactive metabolites, QPL621 and FRK011.

Results

Fifty-six participants enrolled (single ascending doses, n = 24; multiple ascending doses, n = 24; food effect, n = 8). EDI048 was well tolerated up to 400 mg twice daily for 5.5 days. Few treatment-emergent adverse events occurred, mostly mild and unrelated to study drug. No deaths or drug-related serious adverse events occurred. Dose-proportional exposure was noted for EDI048, QPL621, and FRK011. PK analyses suggested substantial conversion of EDI048 to QPL621. No significant accumulation occurred with multiple dosing. Food intake marginally increased EDI048 exposure. No clinically significant changes in electrocardiogram, laboratory, or vital sign parameters were observed.

Conclusions

EDI048 had an acceptable safety profile at all doses tested, up to 400 mg orally administered twice daily for 5.5 days. PK analysis showed minimal systemic exposure of EDI048 in healthy adults. These results support further clinical development for cryptosporidiosis. Clinical Trials Registration NCT05275855.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CryptosporidiosisAntiprotozoal AgentsHumansAdultMaleFemaleYoung AdultMiddle AgedHealthy VolunteersAdolescentDouble-Blind MethodPlacebosDose-Response Relationship, Drug

Stichwörter der Autor:innen

EDI048cryptosporidiosispharmacokineticsphosphatidylinositol 4-kinase inhibitorsafety

Substanzen

Antiprotozoal AgentsPlacebos

Autor:innen und Institutionen

  • Biomedical Research, Novartis, Cambridge, Massachusetts, USA.
  • Biomedical Research, Novartis Pharmaceuticals AG, Basel, Switzerland.
  • Global Health, Biomedical Research, Novartis, Emeryville, California, USA.
  • Technical Research Development, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
  • Technical Research Development, Novartis Pharmaceuticals AG, Basel, Switzerland.

ORCID-Profile: Rajiv S Jumani, Johanne Blais, Joseph Etse, Ujjini H Manjunatha, Bridget D Stuart

Förderung

  • Novartis BioMedical Research

Zitieren

APA

Jain, M., Stevenson, K., Cheblal, A., Iyer, G., Gholamreza, R., Galarneau, J. R., Braud-Perez, S., Jumani, R. S., Blais, J., Etse, J., Dederichs, J., Zhang, Y., Arora, K., Beecham, R. K., Prince, W., Manjunatha, U. H., & Stuart, B. D. (2026). A First-in-Human Phase 1 Clinical Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of EDI048, a Novel Promising Agent to Treat Enteric Cryptosporidiosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag210

Vancouver

Jain M, Stevenson K, Cheblal A, Iyer G, Gholamreza R, Galarneau JR, et al. A First-in-Human Phase 1 Clinical Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of EDI048, a Novel Promising Agent to Treat Enteric Cryptosporidiosis. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag210

BibTeX
@article{Jain2026,
  author = {Jain, Monish and Stevenson, Kristen and Cheblal, Anais and Iyer, Ganesh and Gholamreza, Rahmanzadeh and Galarneau, Jean-Rene and Braud-Perez, Sofia and Jumani, Rajiv S and Blais, Johanne and Etse, Joseph and Dederichs, Juergen and Zhang, Yiming and Arora, Kriti and Beecham, Robert K and Prince, William and Manjunatha, Ujjini H and Stuart, Bridget D},
  title = {A First-in-Human Phase 1 Clinical Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of EDI048, a Novel Promising Agent to Treat Enteric Cryptosporidiosis},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag210}
}
Kostenlos starten →